Dr. Crowe envisions a future where antibody manufacturing is decentralized. A device, similar to a 3D printer, could download a specific antibody "recipe" and produce it on-site at a pharmacy or even in a home, revolutionizing rapid response and personalized medicine.

Contrary to the popular belief that antibody development is a bespoke craft, modern methods enable a reproducible, systematic engineering process. This allows for predictable creation of antibodies with specific properties, such as matching affinity for human and animal targets, a feat once considered a "flight of fancy."

The rationale for "virus hunting" is to create advance vaccines. However, you cannot safely test a vaccine for a novel, deadly pathogen on healthy humans. This makes the knowledge unactionable for prevention, while creating immense risk by bringing dangerous pathogens into leaky labs and publicizing their existence.

The field of infectious disease is moving away from empirical treatment toward its own version of precision medicine. Similar to how oncology uses companion diagnostics to guide therapy, new rapid molecular tests are enabling clinicians to identify the specific organism and its resistance profile to prescribe the right antibiotic at the right time.

Advances in antibody engineering (long half-life, high potency) mean they can now provide year-long protection from a single injection. This positions them as a direct alternative to vaccines for prevention, shifting the paradigm from "vaccinating people" to "making people immune" by any effective means.

The next major biological threat may not be a single event like COVID-19, but rather 'waves and waves of new pandemics.' This is due to the increasing accessibility and decreasing cost of the knowledge and equipment needed to create novel pathogens, potentially allowing individuals to tinker with viruses in their basements, leading to frequent lab leaks.

Agencies like BARDA are funding drugs that treat severe symptoms common to various pathogens, such as acute respiratory distress syndrome (ARDS). This strategy aims to have pre-approved, pathogen-agnostic treatments available immediately during a new pandemic to reduce mortality while vaccines are developed.

Dr. Crowe believes AI's most immediate impact isn't designing new antibodies from scratch. Instead, it's analyzing vast datasets to predict which newly discovered antibodies are developable (stable, high-expression), preventing investment in potent molecules that ultimately can't be manufactured at scale.

Andrew Lo advocates funding a diverse portfolio of drug candidates. By taking “multiple shots on goal,” the high risk of individual failures is mitigated. The immense success of just one or two approved drugs can financially cover the costs of the entire portfolio, making early-stage biotech investment more viable and rational.